In Vitro Diagnostics
Transforming novel biochemical processes into high-value diagnostic platforms
vivoDx System with Smarticles Technology Disposables
A simple and elegant workflow to utilize GeneWEAVE’s transformative Smarticles technology on a platform for the prevention and treatment guidance of multidrug-resistant organisms (MDRO).
The Ximedica and GeneWEAVE teams collaborated on concept development of a revolutionary, low-cost disposable for sample-Smarticle processing and high-sensitivity, automated chemiluminescence detection. Ximedica incorporated their proprietary line of automation components to create a fully automated, continuous (random) access instrument and integrated disposable handling.
The collaboration’s success attracted interest from multiple investors and culminated in Roche Diagnostics acquiring GeneWEAVE in 2015 for $425M total consideration.